Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients [Phase 2]
Phase 2 study evaluating second-line ramucirumab with or without paclitaxel in elderly patients with advanced gastric or gastroesophageal ju…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial is evaluating FOLFIRI plus Durvalumab versus FOLFIRI plus Durvalumab and Tremelimumab as second-line treatment for …
-
CLINICAL_TRIALS research · 2024-06-27Clinical Trial Update: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer [Phase 2]
A Phase 2 trial is evaluating AK104 with AK112 and SOX/XELOX chemotherapy as first-line treatment for advanced gastric and gastroesophageal …
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]
Phase 2 clinical trial of iTTo in treatment-naive advanced gastric cancer and gastroesophageal junction adenocarcinoma has completed.
-
CLINICAL_TRIALS research · 2024-06-12Clinical Trial Update: Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer [Phase 2]
A Phase 2 clinical trial is evaluating whether adding Fruquintinib to Sintilimab and chemotherapy improves outcomes versus Sintilimab and ch…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 trial of ramucirumab plus irinotecan in previously treated advanced gastric or gastroesophageal junction adenocarcinoma has comple…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating paclitaxel with apatinib and adebrelimab in gastric/gastroesophageal junction adenocarcinoma, currently re…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma [Phase 2]
Phase II neoadjuvant pembrolizumab trial for early-stage gastroesophageal junction, gastric, and esophageal adenocarcinoma has been terminat…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports results for a combination of liposomal irinotecan, fluorouracil, leucovorin, and rucaparib in pati…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer [Phase 2]
Phase 2 clinical trial evaluating RC48 (disitamab vedotin) combined with Adebrelimab, Apatinib, and S-1 as neoadjuvant therapy for locally a…
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin [Phase 2]
A Phase 2 clinical trial is evaluating cadonilimab plus fruquintinib and paclitaxel-albumin as second-line therapy for advanced gastric/gast…
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy [Phase 2, Phase 3]
Phase 2/3 trial evaluating DV in combination with cadonilimab for HER2-expressing gastric cancer and gastroesophageal junction adenocarcinom…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. [Phase 3]
A phase 3 trial evaluating M108 plus CAPOX versus placebo plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative, PD-L1 CPS…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 trial update evaluating SHR-1210 with trastuzumab, oxaliplatin, and capecitabine as neoadjuvant therapy for gastric adenocarcinoma…
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]
Phase 2 trial evaluating induction chemotherapy with trifluridine/tipiracil and oxaliplatin for resectable esophageal or gastroesophageal ju…
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen [Phase 3]
Phase 3 clinical trial update for SHR-A1811 in HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma after progr…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma [Phase 3]
Phase 3 trial update for CS1001 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) [Phase 3]
Phase 3 trial MK-3475-859 (KEYNOTE-859) evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric/GEJ adenocarc…
-
CLINICAL_TRIALS trial_result · 2023-08-29Clinical Trial Update: Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial of VE800 in combination with nivolumab has completed enrollment and posted results for selected advanced cancers. T…
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors [Phase 1, Phase 2]
Clinical trial update on Q-1802 combined with XELOX in gastrointestinal tumors, currently in Phase 1/Phase 2 for gastroesophageal junction a…
-
CLINICAL_TRIALS trial_result · 2023-07-10Clinical Trial Update: Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer [Phase 1, Phase 2]
Phase 1/2 trial investigating taladegib with paclitaxel, carboplatin, and radiation therapy for localized esophageal or gastroesophageal jun…
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction [Phase 2]
Phase 2 trial evaluating neoadjuvant chemoradiation combined with serplulimab in locally advanced gastroesophageal junction adenocarcinoma; …
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis [Phase 2]
Phase 2 trial of pembrolizumab in advanced gastric or gastroesophageal junction adenocarcinoma after progression on platinum/fluoropyrimidin…
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) [Phase 3]
Phase 3 trial comparing pembrolizumab to paclitaxel in Asian patients with advanced gastric or gastroesophageal junction adenocarcinoma afte…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 1, Phase 2]
Phase 1/2 trial update evaluating IRX-2, cyclophosphamide, and pembrolizumab in recurrent or metastatic gastric or gastroesophageal junction…